Search results
Results from the WOW.Com Content Network
Net income. US$3.62 billion (2023) Total assets: US$22.7 billion ... Vertex Pharmaceuticals Incorporated is an American biopharmaceutical company based in Boston, ...
VRTX data by YCharts. With the biotech company's stock already posting impressive gains of over 9% in early 2025, it's worth examining whether Vertex stock remains a compelling buy right now.
With Vertex Pharmaceuticals ... Is the stock worth buying? ... It didn't need anything like Ozempic to increase its trailing-12-month net income by nearly 102% during the past three years ...
Joshua S. Boger (born April 12, 1951) is an organic chemist and the founder of Vertex Pharmaceuticals Incorporated. He is considered a pioneer in the field of structure-based rational drug design . Drugs developed include amprenavir , an HIV protease inhibitor ; telaprevir , a protease inhibitor for treatment of hepatitis C ; and Kalydeco , for ...
Shares of Vertex Pharmaceuticals (NASDAQ: VRTX) are down about 9% from a peak the stock set in November, despite some highly positive news. The U.S. Food and Drug Administration (FDA) approved ...
Reshma Kewalramani, is the president and chief executive officer of Vertex Pharmaceuticals, a biotechnology company based in Boston, Massachusetts, as of April 1, 2020. [1] [2] [3] She is the first female CEO of a large US biotech company. [2]
Jeffrey Leiden is an American physician, scientist and businessman who is the executive chairman of Vertex Pharmaceuticals, a biotechnology company based in Boston, Massachusetts. [1] He was initially appointed to the board of directors of the company in 2009 and was CEO and president from February 2012 to March 2020.
VRTX Free Cash Flow data by YCharts.. On top of this, Vertex has a huge amount of cash -- $14.6 billion at the end of the first quarter -- thanks to solid revenue growth.